NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free CVM Stock Alerts $1.48 +0.06 (+4.23%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.41▼$1.4950-Day Range$1.41▼$2.4152-Week Range$1.04▼$3.23Volume133,299 shsAverage Volume283,034 shsMarket Capitalization$79.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get CEL-SCI alerts: Email Address Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About CEL-SCI Stock (NYSE:CVM)CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More CVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVM Stock News HeadlinesApril 23, 2024 | businesswire.comCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsApril 16, 2024 | businesswire.comChannel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentMay 3, 2024 | StockEarnings (Ad)The AI Stock that’s Disrupting Every IndustryMove over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…April 15, 2024 | finance.yahoo.comCVM: Parallel Engagement on Four FrontsApril 12, 2024 | msn.comScientists produce in vitro model of cell differentiation during early facial developmentApril 9, 2024 | msn.comResearchers discover two vesicle fusion mechanisms while studying vesicle movement in living cellsApril 6, 2024 | seekingalpha.comCVM CEL-SCI CorporationMarch 28, 2024 | msn.comCross-species insights: Study finds calcium link in plant and animal immunityMay 3, 2024 | StockEarnings (Ad)The AI Stock that’s Disrupting Every IndustryMove over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…March 19, 2024 | stockhouse.comCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 19, 2024 | finance.yahoo.comCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 11, 2024 | msn.comResearchers reveal a new mechanism that regulates intestinal stem cellsMarch 6, 2024 | businesswire.comCEL-SCI Corporation Issues Letter to ShareholdersFebruary 23, 2024 | finance.yahoo.comCVM Apr 2024 4.000 callFebruary 15, 2024 | finance.yahoo.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 15, 2024 | businesswire.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 13, 2024 | finance.yahoo.comCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockFebruary 12, 2024 | seekingalpha.comCel-Sci: Fabulous Story Stock Works To Pass Muster With FDAFebruary 9, 2024 | msn.comWhy CEL-SCI Corporation (CVM) Shares Are DivingFebruary 9, 2024 | finance.yahoo.comCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockFebruary 6, 2024 | stockhouse.comCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugJanuary 31, 2024 | stockhouse.comEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®January 8, 2024 | finance.yahoo.comCVM: Fiscal Year 2023 in ReviewDecember 22, 2023 | finance.yahoo.comCEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsDecember 14, 2023 | morningstar.comCEL-SCI Corp CVMDecember 8, 2023 | finance.yahoo.comCVM: NICE To Have Your SupportDecember 4, 2023 | barrons.comUK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck CancerSee More Headlines Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/03/2024Next Earnings (Estimated)5/10/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CVM CUSIPN/A CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-204.28% Return on Assets-95.72% Debt Debt-to-Equity Ratio0.75 Current Ratio1.26 Quick Ratio0.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book5.29Miscellaneous Outstanding Shares53,980,000Free Float45,213,000Market Cap$79.89 million OptionableOptionable Beta1.23 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Geert R. Kersten Esq. (Age 65)Chief Executive & Financial Officer, Treasurer and Director Comp: $702.79kMs. Patricia B. Prichep (Age 73)Senior VP of Operations & Corporate Secretary Comp: $295.18kDr. Eyal Talor Ph.D. (Age 68)Chief Scientific Officer Comp: $351.88kDr. Daniel H. Zimmerman Ph.D. (Age 83)Senior Vice President of Research & Cellular Immunology Comp: $46.08kMr. John Cipriano (Age 82)Senior Vice President of Regulatory Affairs Comp: $246.97kKey CompetitorsCognition TherapeuticsNASDAQ:CGTXGritstone bioNASDAQ:GRTSPassage BioNASDAQ:PASGAthira PharmaNASDAQ:ATHAAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInstitutional OwnershipForthright Family Wealth Advisory LLCBought 16,500 shares on 2/28/2024Ownership: 0.031%Cantor Fitzgerald L. P.Bought 121,000 shares on 2/15/2024Ownership: 0.241%Tower Research Capital LLC TRCBought 15,431 shares on 2/13/2024Ownership: 0.032%D.A. Davidson & CO.Bought 247,128 shares on 2/9/2024Ownership: 0.582%Thoroughbred Financial Services LLCBought 25,000 shares on 2/9/2024Ownership: 0.254%View All Institutional Transactions CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed in 2024? CEL-SCI's stock was trading at $2.72 at the beginning of the year. Since then, CVM shares have decreased by 45.6% and is now trading at $1.48. View the best growth stocks for 2024 here. When is CEL-SCI's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CVM earnings forecast. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.14) EPS for the quarter. What ETF holds CEL-SCI's stock? Amplify Treatments, Testing and Advancements ETF holds 12,734 shares of CVM stock, representing 0.22% of its portfolio. When did CEL-SCI's stock split? CEL-SCI's stock reverse split on the morning of Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, Peter R Young and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CVM) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetry$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
